|
Post by buyitonsale on Sept 12, 2017 12:09:22 GMT -5
Some quotes from presentation that I enjoyed:
"before you go out and contract and lock up your pricing for 3 years, if you do get a new category with our label change, which could be ultra acting, that really sets a different contracting strategy and price points"
"when we recapitalize the company, the proceeds of that will be looking to do one of two things, scale up consumer and /or scale up our sales force to cover primary care docs even more. We do believe there is a large opportunity sitting there, that primary care docs are willing to prescribe the drug"
|
|
|
Post by nylefty on Sept 12, 2017 12:10:55 GMT -5
Yah he just posted the Merck statement again this AM. Wall street posted a reply yesterday on Castagna's twitter feed saying that MNKD had met with MRK at / after the investor conference. Wish Castagna would acknowledge the comment and confirm or deny. Really? Have you read this guy's disclaimers? "everything you read in this section is purely for entertainment value and can be considered untrue and a fantasy of our publishers mind!"
His fake news pumping doesn't deserve any comment.
|
|
|
Post by straightly on Sept 12, 2017 12:36:58 GMT -5
Some quotes from presentation that I enjoyed: "before you go out and contract and lock up your pricing for 3 years, if you do get a new category with our label change, which could be ultra acting, that really sets a different contracting strategy and price points" "when we recapitalize the company, the proceeds of that will be looking to do one of two things, scale up consumer and /or scale up our sales force to cover primary care docs even more. We do believe there is a large opportunity sitting there, that primary care docs are willing to prescribe the drug" This is just wonderful. Whatever Mike has, he can show to an invester that this is no longer a feasibility issue: the feasibility issue has been resolved and he has the data proving it. Now it is ONLY a leveraging/number issue: with this much, we can add this many sales and do this much DTC and survive. With that much, we can add that many sales and that much DTC and grow that much faster. We had already convince/assured our toughest invester Deerfield. It is the toughest because they already has leverage AGAINST us, they choosed NOT to use it because Mike convince them it is better this way to Deearfield's interests. Go Mike. Go MNKD.
|
|
|
Post by mnkdfann on Sept 12, 2017 12:43:35 GMT -5
Some quotes from presentation that I enjoyed: "before you go out and contract and lock up your pricing for 3 years, if you do get a new category with our label change, which could be ultra acting, that really sets a different contracting strategy and price points" The only way I can read that, is he thinks insurers and individuals will pay MORE for Afrezza. Is that realistic? And isn't that (charging more for Afrezza) sort of counter what most people on this board are arguing for?
|
|
|
Post by dreamboatcruise on Sept 12, 2017 12:54:27 GMT -5
Some quotes from presentation that I enjoyed: "before you go out and contract and lock up your pricing for 3 years, if you do get a new category with our label change, which could be ultra acting, that really sets a different contracting strategy and price points" The only way I can read that, is he thinks insurers and individuals will pay MORE for Afrezza. Is that realistic? And isn't that (charging more for Afrezza) sort of counter what most people on this board are arguing for? That only has to do with pricing to the insurers. If anything the pricing to their customers would go down if tier placement is improved. Can't imagine a new label could cause worse tier placement on formularies. Is it realistic that insurers would pay more? Perhaps, if they start to believe it could result in near term cost savings in other ways. And we have no idea what the "more" is in relation to since we have no idea what pricing MNKD has offered the insurers that have already gotten on board. Perhaps even after a positive label change, Afrezza would be priced for insurers no more than RAAs... perhaps not... we have NO way of knowing since that info is tightly held trade secret.
|
|
|
Post by casualinvestor on Sept 12, 2017 13:35:41 GMT -5
Some quotes from presentation that I enjoyed: "before you go out and contract and lock up your pricing for 3 years, if you do get a new category with our label change, which could be ultra acting, that really sets a different contracting strategy and price points" The only way I can read that, is he thinks insurers and individuals will pay MORE for Afrezza. Is that realistic? And isn't that (charging more for Afrezza) sort of counter what most people on this board are arguing for? Or that he's waiting for a label change to see if they should "give in" and cut deals on Afrezza to get on more pre-approved lists
|
|
|
Post by liane on Sept 12, 2017 14:18:47 GMT -5
Can we please stop reposting FUD from other sites?
|
|
|
Post by uvula on Sept 12, 2017 19:01:53 GMT -5
I agree. Only post FUD here if you created it yourself.
|
|
|
Post by mnholdem on Sept 12, 2017 20:33:24 GMT -5
Excerpt from Rodman & Renshaw Conference
Michael Castagna - CEO MannKind Corporation
I’ll talk about the commercial execution on the next Slide, but the two things on this slide that are important is One Drop collaboration. So we announced this collaboration back in May. We announced the study in June-July timeframe around a Type 2 patient [Indiscernible] study. That study is meant to use technology and integrating dosing and also potentially moving into a membership model. When you think about the world of convenience and where people are going, there is $300 million cash market in the diabetes market just on insulin alone. If you look at the average out of pocket those patients are paying, they’re not on the Wal-Mart brand, a lot of them are paying a significant amount of money. And so we’re looking at how do we change that mechanism to be more of a membership model and in collaboration with One Drop, so that’s something we continue to look and design. Because it’s not really been done in healthcare and pharmaceuticals, it takes a while to get through all the legal challenges and government pricing things. But we’re working through those as we speak.
---
Is this doable? OneDrop Premium is a subscription-based model that offers the tester, Bluetooth software to your smart device and unlimited test strips for a low monthly fee. Will MannKind be able to clear hurdles (legal, pricing) to do something similar to OneDrop and successfully pull it off?
|
|
|
Post by buyitonsale on Sept 12, 2017 22:56:14 GMT -5
When two inspired entrepreneurs put their minds together, yes I think they can
|
|
|
Post by itellthefuture777 on Sept 12, 2017 23:23:43 GMT -5
Excerpt from Rodman & Renshaw Conference Michael Castagna - CEO MannKind Corporation I’ll talk about the commercial execution on the next Slide, but the two things on this slide that are important is One Drop collaboration. So we announced this collaboration back in May. We announced the study in June-July timeframe around a Type 2 patient [Indiscernible] study. That study is meant to use technology and integrating dosing and also potentially moving into a membership model. When you think about the world of convenience and where people are going, there is $300 million cash market in the diabetes market just on insulin alone. If you look at the average out of pocket those patients are paying, they’re not on the Wal-Mart brand, a lot of them are paying a significant amount of money. And so we’re looking at how do we change that mechanism to be more of a membership model and in collaboration with One Drop, so that’s something we continue to look and design. Because it’s not really been done in healthcare and pharmaceuticals, it takes a while to get through all the legal challenges and government pricing things. But we’re working through those as we speak.
--- Is this doable? OneDrop Premium is a subscription-based model that offers the tester, Bluetooth software to your smart device and unlimited test strips for a low monthly fee. Will MannKind be able to clear hurdles (legal, pricing) to do something similar to OneDrop and successfully pull it off? I can imagine the Bluehaler attached to dreamboat inhaler to automatically corralate time in inhalation to One drop device automatically..as an option on a membership..hmm
|
|
|
Post by dreamboatcruise on Sept 13, 2017 1:09:47 GMT -5
Excerpt from Rodman & Renshaw Conference Michael Castagna - CEO MannKind Corporation I’ll talk about the commercial execution on the next Slide, but the two things on this slide that are important is One Drop collaboration. So we announced this collaboration back in May. We announced the study in June-July timeframe around a Type 2 patient [Indiscernible] study. That study is meant to use technology and integrating dosing and also potentially moving into a membership model. When you think about the world of convenience and where people are going, there is $300 million cash market in the diabetes market just on insulin alone. If you look at the average out of pocket those patients are paying, they’re not on the Wal-Mart brand, a lot of them are paying a significant amount of money. And so we’re looking at how do we change that mechanism to be more of a membership model and in collaboration with One Drop, so that’s something we continue to look and design. Because it’s not really been done in healthcare and pharmaceuticals, it takes a while to get through all the legal challenges and government pricing things. But we’re working through those as we speak.
--- Is this doable? OneDrop Premium is a subscription-based model that offers the tester, Bluetooth software to your smart device and unlimited test strips for a low monthly fee. Will MannKind be able to clear hurdles (legal, pricing) to do something similar to OneDrop and successfully pull it off? I can imagine the Bluehaler attached to dreamboat inhaler to automatically corralate time in inhalation to One drop device automatically..as an option on a membership..hmm This has already been discussed quite at length in other threads, but the current bluehaler makes the dreamboat quite a bit larger (no longer pocket sized in my opinion) and one would still need to record the dose (which cartridge) as that wouldn't be known by bluehaler... and if one has to enter dose there really isn't any advantage to having the bluehaler. Already the user is entering things like meals into OneDrop. It doesn't seem like a lot of burden to do a few clicks to open app and do add "8u inhale")... might take 3 seconds.
|
|
|
Post by mango on Sept 13, 2017 2:15:23 GMT -5
I can imagine the Bluehaler attached to dreamboat inhaler to automatically corralate time in inhalation to One drop device automatically..as an option on a membership..hmm This has already been discussed quite at length in other threads, but the current bluehaler makes the dreamboat quite a bit larger (no longer pocket sized in my opinion) and one would still need to record the dose (which cartridge) as that wouldn't be known by bluehaler... and if one has to enter dose there really isn't any advantage to having the bluehaler. Already the user is entering things like meals into OneDrop. It doesn't seem like a lot of burden to do a few clicks to open app and do add "8u inhale")... might take 3 seconds. Entering the info into the app will prob be what happens for now. Maybe a while. A little stationary transmitter in the housing you insert the cartridge into could receive and transmit the data to the app. Whatever the method they use, it will need to be something that does not require any extra steps for the patient and adds zero treatment burden. MannKind does have a patent for a multi-dose inhaler. The inhaler maybe is circular and the disk comprising the cartridges contain 20 cartridges. The muti-dose inhaler could also have additional features: In the multidose embodiments described herein, end-user convenience is optimized. For example, in prandial regimens breakfast, lunch and dinner dosing is achieved for a course of 7 days in a single device. Additional end-user convenience is provided by an indicator mechanism that indicates the day and dosing, for example, day 3 (D3), lunchtime (L).Multi-dose inhaler: Whatever they do, I could see MannKind offering the Bluetooth tech for all inhalers, incorporating the same BluHale inhalation data for the user to see in real time for modifying their technique via OneDrop app, along with tracking lung capacity and more. Maybe they will surprise us.
|
|
|
Post by peppy on Sept 13, 2017 4:35:44 GMT -5
Some quotes from presentation that I enjoyed: "before you go out and contract and lock up your pricing for 3 years, if you do get a new category with our label change, which could be ultra acting, that really sets a different contracting strategy and price points" The only way I can read that, is he thinks insurers and individuals will pay MORE for Afrezza. Is that realistic? And isn't that (charging more for Afrezza) sort of counter what most people on this board are arguing for? what insures pay, and retail prices are two different price points. Part 3 of the new label submission, a label of ultra-rapid, as joey informed us/me, ultra-rapid would be a new shelf. Insurance honors the prescription because there is no cheaper version of the same. The point is, that insurance will pay at all.
Dream insurance coverage in my mind, is the physician prescribes the medication, there is no insurance preauthorization requirement, and the copay is 30-35 dollars. That's when we see type twos get on board?
|
|